
MDXG — MiMedx Group Inc
NASDAQ · Healthcare · Biotechnology
$4.58
+$0.07 (+1.44%)
MiMedx Group Inc (MDXG) is a biotechnology company listed on NASDAQ. It is led by Joseph H. Capper, based in 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062, with about 808 employees. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Latest reported MDXG revenue for 2025-09-30 was $113.7M. Net income was $16.7M. Revenue was up 15.3% from 2025-06-30 to 2025-09-30. MDXG currently screens at market cap $537.7M and trailing P/E 18.1.
Use this MDXG page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MDXG quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MDXG SEC filings page. Lician reads the product cache first so this HTML stays unique to MiMedx Group Inc even when a live quote feed is slow.
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
MDXG Key Statistics
Market Cap
$537.69M
Volume
711,020
Previous Close
$4.34
Day Range
$4.27 – $4.44
P/E Ratio
18.05
EPS
$0.28
Revenue
$348.88M
Net Income
$42.42M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+8.5%
Profit Margin
12.2%
Employees
808
MDXG Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $348.88M | $321.48M | $267.84M | $242.02M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $42.42M | $58.23M | -$30.20M | -$10.29M |
| EPS (Diluted) | $0.28 | $0.37 | -$0.33 | -$0.15 |
Total Assets
$263.92M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$104.42M
Operating Cash Flow
$66.20M
Free Cash Flow
$0.00
MiMedx Group Inc Company Information
- CEO & Director
- Joseph H. Capper
- Headquarters
- 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
- Website
- www.mimedx.com
- Phone
- 770 651 9100
- IPO / Founded
- 2007-08-22
- Sector
- Healthcare
- Industry
- Biotechnology